Lanean...

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an oral pan-HDACi, in a first-in-man phase 1 dose escala...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leuk Lymphoma
Egile Nagusiak: Sborov, Douglas W., Canella, Alessandro, Hade, Erinn M., Mo, Xiaokui, Khountham, Soun, Wang, Jiang, Ni, Wenjun, Poi, Ming, Coss, Christopher, Liu, Zhongfa, Phelps, Mitch A., Mortazavi, Amir, Andritsos, Leslie, Baiocchi, Robert A., Christian, Beth A, Benson, Don M., Flynn, Joseph, Porcu, Pierluigi, Byrd, John C., Pichiorri, Flavia, Hofmeister, Craig C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5489371/
https://ncbi.nlm.nih.gov/pubmed/28270022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1298751
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!